So far, many BTK inhibitors have been approved for marketing globally, with 5 drugs already approved for marketing in China and several others in clinical research. After a careful assessment of the market competition, development progress, expected scale of investment in subsequent registration clinical trials, future market share, and commercial returns of the candidate drug SY-1530, the company has decided to adjust the subsequent development strategy of SY-1530, actively terminating its clinical development in single-drug treatment of relapsed/refractory mantle cell lymphoma (MCL) and other B-cell non-Hodgkin's lymphoma (NHL) subtypes; in the future, the company plans to explore the potential of SY-1530 in other indications.
SY-1530 (Note: Since 2016, the company has used 'SY' as the naming convention for its self-developed pipeline. When searching on official platforms like the National Medical Products Administration, 'CT-1530' should be used) is a high-selective, irreversible new generation BTK kinase inhibitor independently developed by the company. According to the relevant regulations of the 'Classification and Registration Requirements for Chemical Drug Registrations,' the raw materials and formulations of SY-1530 belong to Class 1 new drugs, and in August 2016, it obtained clinical approval.
